John Sunyecz, MD
Obstetrics & Gynecology · Hopwood, PANPI 1316982416
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Minerva Surgical, Inc accounts for 65.7% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $12,977 and has fallen 98.5% since, to $195 in 2025. Among obstetrics & gynecology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $169.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Minerva Surgical, Inc$14K
- AMAG Pharmaceuticals, Inc.$4K
- Coloplast$839
- Medical Device Business Services, Inc.$507
- Coopersurgical, Inc.$224
- AbbVie$193
- plus $977 from 22 others
What the payments were for
- Consulting fees$3,65017%
- Speaking & faculty fees$9,30045%
- Travel & lodging$5,35126%
- Food & beverage$2,56612%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Minerva Surgical, Inc | 32 | $13,703 |
| AMAG Pharmaceuticals, Inc. | 9 | $4,426 |
| Coloplast | 11 | $839 |
| Medical Device Business Services, Inc. | 5 | $507 |
| Coopersurgical, Inc. | 5 | $224 |
| AbbVie | 11 | $193 |
| Boston Scientific | 5 | $96 |
| Organon | 5 | $87 |
| Astellas Pharma US Inc | 4 | $84 |
| Bayer | 3 | $83 |
| Dilon Technologies, Inc. | 2 | $81 |
| Exact Sciences | 4 | $73 |
| Amgen | 4 | $67 |
| Pfizer | 3 | $61 |
| Axonics, Inc. | 3 | $48 |
| Davol Inc. | 1 | $36 |
| Exeltis, USA Inc. | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Covidien LP | 2 | $30 |
| Cumberland Pharmaceuticals, Inc. | 2 | $28 |
| Mylan Pharmaceuticals Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Therapeuticsmd, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Urovant Sciences Inc | 1 | $15 |
| Myovant Sciences Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Endometrial Ablation System (Device)$8,216
- VYLEESI$4,241
- ALTIS$262
- RESTORELLE$229
How this compares
$20,869 in reported general payments places this provider in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 47 | $81,034 |
| PremarinEstrogens, Conjugated | 78 | $33,451 |
| MyrbetriqMirabegron | 41 | $29,755 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 12 | $28,182 |
| Estradiol | 121 | $7,955 |
| Mirabegron ErMirabegron | 16 | $7,217 |
| VeozahFezolinetant | 15 | $6,886 |
| Risedronate Sodium | 87 | $4,114 |
| Ibandronate Sodium | 148 | $3,186 |
| DottiEstradiol | 19 | $2,459 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 105 | $2,099 |
| Trospium Chloride ErTrospium Chloride | 11 | $1,902 |
| Solifenacin Succinate | 39 | $1,055 |
| Estradiol (Once Weekly)Estradiol | 14 | $897 |
| Buspirone Hcl | 33 | $896 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia, Evenity (2 Syringes) | $67 | $109,21759 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $84 | $36,64156 claims |
| PfizerPremarin | $61 | $33,45178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Other obstetrics & gynecology in Hopwood
- Stephen KlaskoPhiladelphia$2.2M
- Stephanie SoberPhiladelphia$1.8M
- Barry JacobsonGlen Mills$302K
- Timothy GrubeFrackville$260K
- Russell StankiewiczLewisburg$202K
- Jamille Nagtalon-RamosPhiladelphia$183K
- Timothy DeimlingMechanicsburg$182K
- Gerald HarkinsMechanicsburg$140K
- Kirthik ParthasarathyWest Reading$103K
- Catherine ChappellPittsburgh$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.